Literature DB >> 9786474

Escherichia coli O157 interactions with human intestinal Caco-2 cells and the influence of fosfomycin.

K Izumikawa1, Y Hirakata, T Yamaguchi, H Takemura, S Maesaki, K Tomono, S Igimi, M Kaku, Y Yamada, S Kohno, S Kamihira.   

Abstract

It is not clear how Escherichia coli O157 invades human enteric epithelium and causes the haemolytic uraemic syndrome (HUS), and nor has the most appropriate treatment of E. coli O157 infection been established. Verotoxins, leucocytes and proinflammatory cytokines, such as tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and IL-8, are considered essential for the development of HUS. We used the Caco-2 cell monolayer system, well-known as an in-vitro model of human intestinal infection, to determine how E. coli O157 interacts with intestinal epithelial cells and also studied the influence of fosfomycin on the virulence of the bacteria. Results showed that the E. coli O157 used in this study did not penetrate the Caco-2 cell monolayer system, unlike Salmonella typhimurium SL1344, and verotoxin 1 (VT 1), but not VT 2, translocated across the system. In an in-vitro conventional assay, fosfomycin increased the amount of verotoxins but it did not influence penetration of bacteria and translocation of verotoxins in the Caco-2 cell monolayer system. The production of both IL-8 (a potent neutrophil activator) and TNF-alpha in the human monocytic THP-1 cell line was reduced by fosfomycin-treated basolateral medium in this system. These results indicate that fosfomycin may be a potent drug for preventing HUS caused by E. coli O157 infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9786474     DOI: 10.1093/jac/42.3.341

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Shiga Toxin-Producing Escherichia coli.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

2.  Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response.

Authors:  Tatsuki Ohara; Seiichi Kojio; Ikue Taneike; Saori Nakagawa; Fumio Gondaira; Yukiko Tamura; Fumitake Gejyo; Hui-Min Zhang; Tatsuo Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 3.  Small bowel review: diseases of the small intestine.

Authors:  A B Thomson; M Keelan; A Thiesen; M T Clandinin; M Ropeleski; G E Wild
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

Review 4.  Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection.

Authors:  Krystle L Mohawk; Alison D O'Brien
Journal:  J Biomed Biotechnol       Date:  2011-01-03

5.  Characterisation of the E. coli and Salmonella qseC and qseE mutants reveals a metabolic rather than adrenergic receptor role.

Authors:  Abdalla Hamed; Gillian Pullinger; Mark Stevens; Fathima Farveen; Primrose Freestone
Journal:  FEMS Microbiol Lett       Date:  2022-03-04       Impact factor: 2.742

6.  Glycomacropeptide Reduces Intestinal Epithelial Cell Barrier Dysfunction and Adhesion of Entero-Hemorrhagic and Entero-Pathogenic Escherichia coli in Vitro.

Authors:  Shane Feeney; Joseph Thomas Ryan; Michelle Kilcoyne; Lokesh Joshi; Rita Hickey
Journal:  Foods       Date:  2017-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.